Rigel Pharmaceuticals
RIGL
118 hedge funds and large institutions have $143M invested in Rigel Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 32 increasing their positions, 46 reducing their positions, and 12 closing their positions.
822% more call options, than puts
Call options by funds: $1.13M | Put options by funds: $122K
0.1% less ownership
Funds ownership: 6.47% → 6.37% (-0.1%)
4% less capital invested
Capital invested by funds: $149M → $143M (-$5.89M)
5% less funds holding
Funds holding: 124 → 118 (-6)
30% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 46
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.55M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$3.13M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.86M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.16M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$826K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.56M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$2.41M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$1.22M |
| 4 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$1.01M |
| 5 |
Millennium Management
New York
|
-$1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCWA
126
Ten Capital Wealth Advisors
Spokane,
Washington
| – | -$2.64K | -200 | Closed |
|
127
Point72 Asset Management
Stamford,
Connecticut
| – | -$991 | -75 | Closed |
|
|
IAIM
128
International Assets Investment Management
Orlando,
Florida
| – | -$94 | -7 | Closed |
|
RIGL Hedge Fund Activity: Q2 2023 in Review
118 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2023, worth a combined $143M — down 4% from $149M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RIGL and 6 opened new positions — a net loss of 6 holders — while 46 trimmed existing stakes and 32 added.
The largest buyer was Morgan Stanley, adding an estimated $4.55M. The largest seller was Fidelity Investments, cutting an estimated $3.56M.
- 118 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2023, down from 124 in Q1 2023.
- Funds reported $143M of Rigel Pharmaceuticals stock for Q2 2023, down 4% quarter-over-quarter.
- 6 funds opened new Rigel Pharmaceuticals positions in Q2 2023 and 12 closed out, a net change of -6 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2023 was Morgan Stanley, an estimated $4.55M added.
- The largest Rigel Pharmaceuticals seller in Q2 2023 was Fidelity Investments, an estimated $3.56M sold.
Based on aggregated 13F filings for Q2 2023.